Literature DB >> 2411793

Carrier-induced epitopic suppression, a major issue for future synthetic vaccines.

M P Schutze, C Leclerc, M Jolivet, F Audibert, L Chedid.   

Abstract

Synthetic antigens have been shown, in experimental models, to induce protective immunity against a variety of pathogens. These studies have demonstrated that, due to their low immunogenicity, these synthetic antigens required conjugation to carrier molecules. Therefore, the choice of appropriate carriers for human immunization by future synthetic vaccines is a major issue. Tetanus toxoid is generally considered to be an effective potential carrier devoid of side-effects. However, the present study performed in mice with two synthetic vaccine models demonstrates that the immune response against the synthetic epitopes conjugated to tetanus toxoid can be suppressed by pre-existing immunity against this same carrier. Because most humans have been exposed to this antigen, this effect may have important implications for the development of synthetic vaccines.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411793

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.

Authors:  C Gravekamp; D L Kasper; L C Paoletti; L C Madoff
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates.

Authors:  P J Brett; D E Woods
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.

Authors:  Karin Baraldo; Elena Mori; Antonella Bartoloni; Francesco Norelli; Guido Grandi; Rino Rappuoli; Oretta Finco; Giuseppe Del Giudice
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites.

Authors:  J U Que; S J Cryz; R Ballou; E Fürer; M Gross; J Young; G F Wasserman; L A Loomis; J C Sadoff
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

5.  Multivalent Antigens for Promoting B and T Cell Activation.

Authors:  Nitasha R Bennett; Daniel B Zwick; Adam H Courtney; Laura L Kiessling
Journal:  ACS Chem Biol       Date:  2015-06-02       Impact factor: 5.100

6.  Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier.

Authors:  L D Lise; D Mazier; M Jolivet; F Audibert; L Chedid; D Schlesinger
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

7.  Isolation and characterization of new human carrier peptides from two important vaccine immunogens.

Authors:  Paeton L Wantuch; Lina Sun; Rachel K LoPilato; Jarrod J Mousa; Robert S Haltiwanger; Fikri Y Avci
Journal:  Vaccine       Date:  2020-01-28       Impact factor: 3.641

8.  Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man.

Authors:  M R Downham; T R Auton; A Rosul; H L Sharp; L Sjöström; A Rushton; J P Richards; T G K Mant; S M Gardiner; T Bennett; J F Glover
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

9.  Bypass of carrier-induced epitope-specific suppression using a T-helper epitope.

Authors:  S Sad; K Rao; R Arora; G P Talwar; R Raghupathy
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

Review 10.  Recent development in carbohydrate-based cancer vaccines.

Authors:  Zhongwu Guo; Qianli Wang
Journal:  Curr Opin Chem Biol       Date:  2009-09-18       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.